Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people can use Wegovy for weight loss for as long as it continues to work and remains clinically appropriate — which for many adults means ongoing treatment rather than a fixed stop date. NICE guidance for NHS use sets a maximum of two years for semaglutide within specialist services, but private prescribing follows the licensed SmPC, which does not impose a hard time limit. These are prescription-only medicines; a prescriber decides how long treatment is right for you, based on your progress, your health, and any side effects along the way.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: six or eight months in, your clothes fit differently, your GP has noticed, and you're wondering whether you still need the pen waiting in the fridge door each week. It's one of the most common questions our prescribers hear. The honest answer is that Wegovy works by actively suppressing appetite through the GLP-1 pathway, and when you stop, that pharmacological effect stops too.
Clinical evidence bears this out clearly. In the STEP 1 extension study, participants who discontinued semaglutide 2.4mg regained most of the weight they had lost within 12 months, even when they continued with lifestyle changes. Weight regain was gradual rather than sudden, but the trajectory was consistent. This does not mean treatment must last forever; it means the decision to stop deserves the same clinical thought as the decision to start.
Questions about how long you can realistically stay on Wegovy depend on your health picture as a whole, not on any fixed calendar. A prescriber weighs up ongoing benefit against any side effects, your weight trajectory, and whether your original weight-related conditions have improved.
For NHS patients, NICE's technology appraisal TA875 is specific: semaglutide (Wegovy) should be used for a maximum of two years, and only within a specialist weight management service offering multidisciplinary support. That two-year cap applies to the NHS route. The guidance also states that if a patient has not achieved at least 5% weight loss after six months at the maintenance dose, continuing is not recommended.
Private prescribing operates under the medicine's licensed SmPC, which does not set a hard two-year ceiling. That makes the prescriber's ongoing clinical judgment the governing factor rather than a fixed end date. In practice, this means how long you take Wegovy is a moving clinical conversation, not a number written in stone at the start.
The 5% threshold matters in both settings. It is a practical checkpoint: if the medicine is not producing meaningful weight loss after six months at the highest dose you tolerate, a prescriber will discuss whether continuing makes sense. This is standard clinical care, not a failure, some people respond better to a different treatment or a different approach.
One thing that catches people out is how the titration schedule stretches the early months. Wegovy starts at 0.25mg weekly, stepping up through 0.5mg, 1.0mg, 1.7mg and finally 2.4mg, with roughly four weeks at each level. That's nearly five months before you reach the maintenance dose at which the STEP 1 trial showed around 15% average weight reduction over 68 weeks. The six-month checkpoint for the 5% rule is counted from the maintenance dose, not from day one.
For those using the newer 7.2mg dose (approved by the MHRA in January 2026, with a dedicated single-dose pen approved in April 2026), the titration path is longer still. The MHRA's approval of the 7.2mg pen confirmed that 0.25mg remains the starting dose and that the maximum dose is reached through the same stepwise schedule. Understanding this timeline helps set realistic expectations for how long Wegovy takes to show meaningful results.
If you are wondering whether the longer duration available through ongoing semaglutide treatment is right for you, that conversation belongs with a prescriber reviewing your full history. Cost is a real consideration for longer treatment; you can explore how Wegovy fits into the range of available options before committing to a consultation.
Longer-term use is not a failure of willpower or a sign that the medicine hasn't worked. Obesity is a chronic condition with a biological basis, and many clinical guidelines now treat it accordingly. The question is not whether you should need the medicine indefinitely, but whether continuing it is medically appropriate and practically sustainable for you.
That sustainability question includes cost, which is worth factoring in from the start. A transparent single price covering consultation, prescription, and free next-working-day delivery matters more over a longer treatment period than it does for a single month. Wegovy pricing and what's included is worth reviewing alongside the clinical picture.
When you're ready to talk through how long treatment might make sense for your situation, a prescriber at our pharmacy will review your consultation the same working day. There are no subscriptions and no auto-renewals; every repeat is a fresh clinical review. Speak to our prescribers through our free consultation page to start that conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.